Cargando…
Plasma-derived phosphoglycerate mutase 5 as a biomarker for Parkinson’s disease
BACKGROUND: We aimed to examine whether plasma-derived phosphoglycerate mutase 5 (PGAM5) can be a biomarker for Parkinson’s disease (PD) diagnosis as well as its association with the severity of motor/non-motor manifestations of PD. METHODS: We enrolled 124 patients with PD (PD group) and 50 healthy...
Autores principales: | Feng, Liang, He, Haijun, Xiong, Xi, Xia, Kai, Qian, Shuangjie, Ye, Qianqian, Feng, Feifei, Zhou, Shuoting, Hong, Xianchai, Liu, Yiming, Xie, Chenglong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9661922/ https://www.ncbi.nlm.nih.gov/pubmed/36389083 http://dx.doi.org/10.3389/fnagi.2022.1022274 |
Ejemplares similares
-
Lewy Body-Associated Proteins A-Synuclein (a-syn) as a Plasma-Based Biomarker for Parkinson’s Disease
por: Zhao, Xuemiao, et al.
Publicado: (2022) -
Identification of Epigallocatechin-3- Gallate as an Inhibitor of Phosphoglycerate Mutase 1
por: Li, Xiaoguang, et al.
Publicado: (2017) -
Development of Anthraquinone Analogues as Phosphoglycerate Mutase 1 Inhibitors
por: Huang, Ke, et al.
Publicado: (2019) -
Structure–activity relationship of ipglycermide binding to phosphoglycerate mutases
por: Wiedmann, Mareike, et al.
Publicado: (2021) -
Phosphoglycerate Mutase Cooperates with Chk1 Kinase to Regulate Glycolysis
por: Mikawa, Takumi, et al.
Publicado: (2020)